InAADR

Drug Information

Drug Name: Fluorouracil (51-21-8)
PubChem ID: 3385
SMILES: C1=C(C(=O)NC(=O)N1)F
InchiKey: GHASVSINZRGABV-UHFFFAOYSA-N
Therapeutic Category: Antimetabolites, Antineoplastic Agents, Immunologic Factors, Immunosuppressive Agents, Noxae

Computed Drug Properties

Molecular Weight (dalton): 130.078
LogP: -0.7977
Ring Count: 1
Hydrogen Bond Acceptor Count: 2
Hydrogen Bond Donor Count: 2
Total Polar Surface Area: 65.72

This panel provides information on interacting drugs and their ADRs along with references

Interacting drug Toxicity Interaction Type Mechanism Reference
Mitomycin (50-07-7) Haemolysis Synergistic Not known Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C
Mitomycin (50-07-7) Renal Impairment Synergistic Not known Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C
Cisplatin (15663-27-1) Anorexia Synergistic Not understood Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-Fluorouracil
Cisplatin (15663-27-1) Diarrhoea Synergistic Not understood Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-Fluorouracil
Cisplatin (15663-27-1) Myelosuppression Synergistic Not understood Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-Fluorouracil
Cisplatin (15663-27-1) Nausea Synergistic Not understood Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-Fluorouracil
Cisplatin (15663-27-1) Stomatitis Synergistic Not understood Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-Fluorouracil
Cisplatin (15663-27-1) Vomiting Synergistic Not understood Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-Fluorouracil
Folic Acid (59-30-3) Anorexia Synergistic folic acid increases fluorouracil inhibition of thymidine formation which is important for DNA synthesis, and thereby increases fluorouracil toxicity. Interaction of 5-fluorouracil with folates
Folic Acid (59-30-3) Bloody Diarrhoea Synergistic folic acid increases fluorouracil inhibition of thymidine formation which is important for DNA synthesis, and thereby increases fluorouracil toxicity. Interaction of 5-fluorouracil with folates
Folic Acid (59-30-3) Mouth Ulceration Synergistic folic acid increases fluorouracil inhibition of thymidine formation which is important for DNA synthesis, and thereby increases fluorouracil toxicity. Interaction of 5-fluorouracil with folates
Folic Acid (59-30-3) Vaginal Bleeding Synergistic folic acid increases fluorouracil inhibition of thymidine formation which is important for DNA synthesis, and thereby increases fluorouracil toxicity. Interaction of 5-fluorouracil with folates
Metronidazole (443-48-1) Anaemia Synergistic Metronidazole reduces the clearance of fluorouracil 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
Metronidazole (443-48-1) Granulocytopenia Synergistic Metronidazole reduces the clearance of fluorouracil 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
Metronidazole (443-48-1) Nausea Synergistic Metronidazole reduces the clearance of fluorouracil 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
Metronidazole (443-48-1) Oral Ulceration Synergistic Metronidazole reduces the clearance of fluorouracil 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
Metronidazole (443-48-1) Stomatitis Synergistic Metronidazole reduces the clearance of fluorouracil 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
Metronidazole (443-48-1) Thrombocytopenia Synergistic Metronidazole reduces the clearance of fluorouracil 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
Metronidazole (443-48-1) Vomiting Synergistic Metronidazole reduces the clearance of fluorouracil 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
Sorivudine (77181-69-2) Anorexia Synergistic Sorivudine appears to be converted in the gut into a metabolite (BVU or bromovinyluracil) that is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), an enzyme involved in the metabolism of fluorouracil Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs

This panel provides drug-protein interaction and their ADRs along with references

Toxicity Interacting Protein Mechanism Reference
Anemia Dihydropyrimidine dehydrogenase (Q12882) Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
Anorexia Dihydropyrimidine dehydrogenase (Q12882) Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
Attenuation Of The Antitumor Activity Dihydropyrimidine dehydrogenase (Q12882) (R)-5-fluoro-5@6-dihydrouracil inactivates dihydropyrimidine dehydrogenase activity@which may lead to attenuation of the antitumor activity of 5-fluorouracil [ ADR Type 4 ] Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil
Bone Marrow Suppression Dihydropyrimidine dehydrogenase (Q12882) Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
Diarrhoea Dihydropyrimidine dehydrogenase (Q12882) Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
Fatigue Dihydropyrimidine dehydrogenase (Q12882) Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
Mucositis Dihydropyrimidine dehydrogenase (Q12882) Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
Myelotoxicity Dihydropyrimidine dehydrogenase (Q12882) myelotoxicity [ ADR Type 1 ] Pharmacogenetics in cancer chemotherapy: balancing toxicity and response
Neurotoxicity Dihydropyrimidine dehydrogenase (Q12882) Neurotoxicity [ ADR Type 1 ] Pharmacogenetics in cancer chemotherapy: balancing toxicity and response
Toxicity Of Fura Chemotherapy Dihydropyrimidine dehydrogenase (Q12882) Decreased DPD protein in the liver cytosol from DPD-deficient patients compared to normal subjects may be useful in improving the effectiveness and/or lessening the toxicity of FUra chemotherapy. [ ADR Type 3 ] Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
Vomiting Dihydropyrimidine dehydrogenase (Q12882) Eniluracil inactivates dihydropyrimidine dehydrogenase activity@bone marrow suppression is the primary and dose-limiting toxicity of this regimen@other toxicities included diarrhea@ mucositis@ anemia@ anorexia@ nausea@ vomiting@ and fatigue [ ADR Type 4 ] Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer

This panel provides drug-food interactions and their ADRs along with references

Food Toxicity Reference

This panel provides information on metabolites and their ADRs along with references

Metabolite Toxicity Place of Metabolism Mechanism Reference

This panel provides information on drug category

Toxicity Source
Abortion Spontaneous ADReCS
Acidosis Lactic MetaADEDB
Acute Coronary Syndrome ADReCS
Acute Kidney Injury MetaADEDB
Acute Pulmonary Oedema ADReCS
Adenocarcinoma MetaADEDB
Adenocarcinoma Mucinous MetaADEDB
Aggression ADReCS
Agranulocytosis ADReCS
Akinetic Mutism MetaADEDB
Allergic Contact Dermatitis ADReCS
Allergy ADReCS
Alopecia ADReCS
Anaemia ADReCS
Anaphylactic Reaction ADReCS
Anaphylactic Shock ADReCS
Anemia MetaADEDB
Anemia Aplastic MetaADEDB
Anemia Hemolytic MetaADEDB
Anemia Hemolytic Autoimmune MetaADEDB
Anemia Macrocytic MetaADEDB
Anemia Megaloblastic MetaADEDB
Angina Pectoris ADReCS
Angina Pectoris Variant MetaADEDB
Angina Unstable MetaADEDB
Angioedema MetaADEDB
Anorexia ADReCS
Anoxia MetaADEDB
Anus Neoplasms MetaADEDB
Aortic Diseases MetaADEDB
Application Site Reaction ADReCS
Arrhythmia ADReCS
Arrhythmias Cardiac MetaADEDB
Arterial Disorder ADReCS
Arterial Occlusive Diseases MetaADEDB
Arteriospasm Coronary ADReCS
Ascites MetaADEDB
Ataxia ADReCS
Atrial Fibrillation MetaADEDB
Atrioventricular Block MetaADEDB
Azotemia MetaADEDB
Biliary Fibrosis ADReCS
Biliary Tract Diseases MetaADEDB
Blepharitis ADReCS
Blister ADReCS
Blood Platelet Disorders MetaADEDB
Bone Marrow Diseases MetaADEDB
Bone Marrow Failure Syndromes MetaADEDB
Bradycardia MetaADEDB
Brain Diseases MetaADEDB
Brain Infarction MetaADEDB
Brain Ischemia MetaADEDB
Breast Neoplasms MetaADEDB
Bulbar Palsy Progressive MetaADEDB
Bundle-Branch Block MetaADEDB
Burning Sensation ADReCS
Carcinoid Tumor MetaADEDB
Carcinoma MetaADEDB
Carcinoma Hepatocellular MetaADEDB
Carcinoma Non-Small-Cell Lung MetaADEDB
Carcinoma Renal Cell MetaADEDB
Carcinoma Squamous Cell MetaADEDB
Carcinoma Squamous Cell Of Head And Neck MetaADEDB
Cardiac Arrest ADReCS
Cardiac Failure ADReCS
Cardiac Septal Defect ADReCS
Cardiomyopathies MetaADEDB
Cardiovascular Diseases MetaADEDB
Cerebellar Ataxia ADReCS
Cerebellar Diseases MetaADEDB
Cerebellar Syndrome ADReCS
Cerebral Infarction MetaADEDB
Cerebrovascular Disorder ADReCS
Chest Pain ADReCS
Cholangitis Sclerosing MetaADEDB
Cholecystitis MetaADEDB
Chronic Conjunctivitis SIDER
Cicatrix MetaADEDB
Cleft Palate MetaADEDB
Cognition Disorders MetaADEDB
Colic MetaADEDB
Colonic Neoplasms MetaADEDB
Colorectal Neoplasms MetaADEDB
Coma MetaADEDB
Condylomata Acuminata MetaADEDB
Confusion MetaADEDB
Confusional State ADReCS
Congenital Anomaly ADReCS
Conjunctivitis ADReCS
Constipation MetaADEDB
Constriction Pathologic MetaADEDB
Convulsion ADReCS
Coronary Artery Disease ADReCS
Coronary Disease MetaADEDB
Coronary Vasospasm MetaADEDB
Dacryocanaliculitis ADReCS
Dacryostenosis Acquired ADReCS
Darier Disease MetaADEDB
Decreased Appetite ADReCS
Dehydration MetaADEDB
Dementia MetaADEDB
Demyelinating Diseases MetaADEDB
Depressive Disorder MetaADEDB
Dermatitis ADReCS
Dermatitis Bullous ADReCS
Dermatitis Contact ADReCS
Dermatomyositis MetaADEDB
Developmental Delay ADReCS
Diarrhea MetaADEDB
Diarrhoea ADReCS
Dihydropyrimidine Dehydrogenase Deficiency SIDER
Discomfort ADReCS
Disorientation ADReCS
Drug Toxicity MetaADEDB
Dry Skin ADReCS
Duodenal Neoplasms MetaADEDB
Dysaesthesia ADReCS
Dysarthria ADReCS
Dysmetria ADReCS
Dyspepsia ADReCS
Dyspnea MetaADEDB
Dyspnoea ADReCS
Dystonia ADReCS
Dysuria MetaADEDB
Ectropion MetaADEDB
Edema MetaADEDB
Embolism MetaADEDB
Emotional Distress ADReCS
Encephalopathy ADReCS
Eosinophilia ADReCS
Epistaxis ADReCS
Erythema ADReCS
Esophageal Neoplasms MetaADEDB
Esophagitis MetaADEDB
Euphoric Mood ADReCS
Extravasation ADReCS
Eye Irritation ADReCS
Eyelid Diseases MetaADEDB
Fatty Liver MetaADEDB
Febrile Neutropenia ADReCS
Feeling Abnormal ADReCS
Fetal Diseases MetaADEDB
Fetal Growth Retardation MetaADEDB
Fever MetaADEDB
Fibrosis ADReCS
Foot Dermatoses MetaADEDB
Gallbladder Neoplasms MetaADEDB
Gastroenteritis MetaADEDB
Gastrointestinal Diseases MetaADEDB
Gastrointestinal Haemorrhage ADReCS
Gastrointestinal Neoplasms MetaADEDB
Gastrointestinal Ulcer ADReCS
Glioma MetaADEDB
Haemoglobin ADReCS
Haemorrhage ADReCS
Hand Dermatoses MetaADEDB
Head And Neck Neoplasms MetaADEDB
Headache ADReCS
Heart Arrest MetaADEDB
Heart Diseases MetaADEDB
Heart Failure MetaADEDB
Heartburn ADReCS
Hemangioendothelioma MetaADEDB
Hematologic Diseases MetaADEDB
Hematuria MetaADEDB
Hemolysis MetaADEDB
Hemolytic-Uremic Syndrome MetaADEDB
Hemorrhage MetaADEDB
Herpes Simplex ADReCS
Herpes Virus Infection ADReCS
Hydronephrosis MetaADEDB
Hyperammonemia MetaADEDB
Hyperpigmentation MetaADEDB
Hypersensitivity ADReCS
Hypertension MetaADEDB
Hypoaesthesia ADReCS
Hypocapnia MetaADEDB
Hypokinesia MetaADEDB
Hyponatremia MetaADEDB
Hypotension ADReCS
Hypovolaemia ADReCS
Ichthyosis ADReCS
Ichthyosis Acquired ADReCS
Inappropriate Adh Syndrome MetaADEDB
Infarction ADReCS
Infection ADReCS
Inflammation ADReCS
Insomnia ADReCS
Intestinal Neoplasms MetaADEDB
Intracranial Embolism MetaADEDB
Intracranial Hemorrhages MetaADEDB
Irritability ADReCS
Ischaemia ADReCS
Ischemia MetaADEDB
Jaundice MetaADEDB
Keratitis MetaADEDB
Keratosis Actinic MetaADEDB
Kidney Diseases MetaADEDB
Kidney Neoplasms MetaADEDB
Lacrimal Apparatus Diseases MetaADEDB
Lacrimation Increased ADReCS
Laryngeal Neoplasms MetaADEDB
Leukocytosis ADReCS
Leukoencephalopathies MetaADEDB
Leukoencephalopathy Progressive Multifocal MetaADEDB
Leukopenia ADReCS
Limb Deformities Congenital MetaADEDB
Liver Abscess MetaADEDB
Liver Cirrhosis MetaADEDB
Liver Cirrhosis Biliary MetaADEDB
Liver Diseases MetaADEDB
Liver Neoplasms MetaADEDB
Liver Neoplasms Experimental MetaADEDB
Lung Neoplasms MetaADEDB
Lupus Erythematosus Cutaneous MetaADEDB
Memory Disorders MetaADEDB
Microcephaly MetaADEDB
Mononeuropathies MetaADEDB
Mouth Neoplasms MetaADEDB
Mucositis MetaADEDB
Mucous Membrane Disorder ADReCS
Muscular Diseases MetaADEDB
Musculoskeletal Discomfort ADReCS
Myalgia ADReCS
Myocardial Infarction ADReCS
Myocardial Ischaemia ADReCS
Myocardial Ischemia MetaADEDB
Myocardial Stunning MetaADEDB
Myocarditis MetaADEDB
Nail Diseases MetaADEDB
Nail Disorder ADReCS
Nasal Discomfort ADReCS
Nasal Irritation ADReCS
Nasopharyngeal Neoplasms MetaADEDB
Nasopharyngitis ADReCS
Nausea ADReCS
Necrosis ADReCS
Neoplasm Metastasis MetaADEDB
Neoplasms MetaADEDB
Neoplasms Experimental MetaADEDB
Nervous System Diseases MetaADEDB
Nervous System Disorder ADReCS
Neuritis MetaADEDB
Neurologic Manifestations MetaADEDB
Neuropathy ADReCS
Neuropathy Peripheral ADReCS
Neurotoxicity Syndromes MetaADEDB
Neutropenia ADReCS
Neutrophil Toxic Granulation Present ADReCS
Nystagmus ADReCS
Ocular Motility Disorders MetaADEDB
Oculomotor Nerve Diseases MetaADEDB
Oedema ADReCS
Oesophagitis ADReCS
Onychomadesis ADReCS
Optic Nerve Diseases MetaADEDB
Optic Nerve Disorder ADReCS
Osteoarthritis ADReCS
Ovarian Neoplasms MetaADEDB
Pain ADReCS
Palmar-Plantar Erythrodysaesthesia Syndrome ADReCS
Pancreatic Neoplasms MetaADEDB
Pancytopenia ADReCS
Paraesthesia ADReCS
Paraneoplastic Syndromes MetaADEDB
Paresthesia MetaADEDB
Parotid Neoplasms MetaADEDB
Pelvic Pain MetaADEDB
Pemphigoid ADReCS
Penile Diseases MetaADEDB
Pericarditis ADReCS
Peripheral Nervous System Diseases MetaADEDB
Pharyngitis ADReCS
Photophobia ADReCS
Photosensitivity Reaction ADReCS
Pica MetaADEDB
Pigmentation Disorder ADReCS
Pigmentation Skin SIDER
Porphyrias MetaADEDB
Posterior Leukoencephalopathy Syndrome MetaADEDB
Postoperative Complications MetaADEDB
Prenatal Injuries MetaADEDB
Prinzmetal Variant Angina MetaADEDB
Proctitis MetaADEDB
Prostatic Neoplasms MetaADEDB
Pruritus ADReCS
Psychotic Disorders MetaADEDB
Pulmonary Edema MetaADEDB
Pulmonary Oedema ADReCS
Rash ADReCS
Rash Maculo-Papular ADReCS
Raynaud Disease MetaADEDB
Rectal Haemorrhage ADReCS
Rectal Neoplasms MetaADEDB
Renal Insufficiency MetaADEDB
Rhinitis ADReCS
Sarcoma MetaADEDB
Scab ADReCS
Scar ADReCS
Scleroderma Limited MetaADEDB
Scleroderma Localized MetaADEDB
Seizures MetaADEDB
Sensory Loss ADReCS
Sepsis MetaADEDB
Sexual Dysfunction Physiological MetaADEDB
Shock Cardiogenic MetaADEDB
Sigmoid Neoplasms MetaADEDB
Sinusitis ADReCS
Skin Discolouration ADReCS
Skin Diseases MetaADEDB
Skin Erosion ADReCS
Skin Exfoliation ADReCS
Skin Fissures ADReCS
Skin Hyperpigmentation ADReCS
Skin Irritation ADReCS
Skin Pigmentation ADReCS
Somnolence ADReCS
Spasm MetaADEDB
Stomach Diseases MetaADEDB
Stomach Neoplasms MetaADEDB
Stomatitis ADReCS
Swelling ADReCS
Tachycardia Sinus MetaADEDB
Tachycardia Supraventricular MetaADEDB
Tachycardia Ventricular MetaADEDB
Takotsubo Cardiomyopathy MetaADEDB
Taste Disorders MetaADEDB
Telangiectasia ADReCS
Telangiectasis MetaADEDB
Tenderness ADReCS
Thiamine Deficiency MetaADEDB
Thrombocytopenia ADReCS
Thromboembolism MetaADEDB
Thrombophlebitis ADReCS
Thrombosis MetaADEDB
Tongue Neoplasms MetaADEDB
Torsades De Pointes MetaADEDB
Tumor Lysis Syndrome MetaADEDB
Ulcer ADReCS
Urinary Bladder Diseases MetaADEDB
Urinary Bladder Neoplasms MetaADEDB
Urticaria ADReCS
Uterine Cervical Neoplasms MetaADEDB
Uterine Neoplasms MetaADEDB
Vaginal Diseases MetaADEDB
Vaginal Neoplasms MetaADEDB
Vascular Malformations MetaADEDB
Vasoconstriction ADReCS
Vasospasm ADReCS
Vein Discolouration ADReCS
Venous Thrombosis MetaADEDB
Ventricular Dysfunction MetaADEDB
Ventricular Dysfunction Left MetaADEDB
Ventricular Fibrillation MetaADEDB
Ventricular Premature Complexes MetaADEDB
Ventricular Septal Defect ADReCS
Vertigo MetaADEDB
Vipoma MetaADEDB
Vision Blurred ADReCS
Vision Disorders MetaADEDB
Visual Impairment ADReCS
Vomiting ADReCS

InAADR: Drug-Protein-ADRs database